A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
University of Washington
InxMed (Shanghai) Co., Ltd.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Children's Oncology Group
Children's Oncology Group
Mayo Clinic
Children's Oncology Group
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Jiangsu Cancer Institute & Hospital
NRG Oncology
NRG Oncology
City of Hope Medical Center
Centre Antoine Lacassagne
NRG Oncology
City of Hope Medical Center
Mayo Clinic
M.D. Anderson Cancer Center
Peking Union Medical College
University of Michigan Rogel Cancer Center
Emory University
Shanghai Junshi Bioscience Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Dana-Farber Cancer Institute
MediLink Therapeutics (Suzhou) Co., Ltd.
Ohio State University Comprehensive Cancer Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Shanghai Pulmonary Hospital, Shanghai, China
Eye & ENT Hospital of Fudan University